Last reviewed · How we verify

Professor Mikkel Østergaard — Portfolio Competitive Intelligence Brief

Professor Mikkel Østergaard pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Apremilast Oral Tablet Apremilast Oral Tablet marketed
Secukinumab 150 milligram [Cosentyx] Secukinumab 150 milligram [Cosentyx] marketed IL-17A inhibitor (monoclonal antibody) IL-17A Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Biocad · 1 shared drug class
  2. Celltrion · 1 shared drug class
  3. Eli Lilly and Company · 1 shared drug class
  4. Fujian Cancer Hospital · 1 shared drug class
  5. Peking Union Medical College · 1 shared drug class
  6. University of Pennsylvania · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Professor Mikkel Østergaard:

Cite this brief

Drug Landscape (2026). Professor Mikkel Østergaard — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/professor-mikkel-stergaard. Accessed 2026-05-16.

Related